Following the manufacturing and marketing approval from DCGI, Hetero is launching remdesivir under the brand COVIFOR in India.
The company secured approval for suspected or laboratory-confirmed Covid-19 cases in hospitalised adults and children. Hetero Group of Companies chairman Partha Saradhi Reddy said: “In the light of increasing Covid-19 cases in India, the approval of ‘COVIFOR’ (Remdesivir) can prove to be a game-changer given its positive clinical outcomes. What do you see as the main benefit of telemedicine?View Results“We are prepared for ensuring enough stocks required to cater to the present needs.